Hepatic Fibrogenesis

Jinsheng Guo; Scott L. Friedman

doi:10.1055/s-2007-991517

Seminars in Liver Disease, Inhaltsverzeichnis

Semin Liver Dis 2007; 27(4): 413-426
DOI: 10.1055/s-2007-991517

Hepatic Fibrogenesis

Jinsheng Guo¹ ^, ² , Scott L. Friedman¹

¹Division of Liver Diseases, Mount Sinai Hospital, Mount Sinai School of Medicine, New York, New York
²Division of Digestive Diseases, Zhongshan Hospital, Department of Internal Medicine, Shanghai Medical College, Fudan University, Shanghai, China

Abstract

ABSTRACT

Hepatic fibrogenesis represents a wound-healing response of liver to a variety of insults, ultimately leading to decompensated cirrhosis in many patients and accounting for extensive morbidity and mortality worldwide. The net accumulation of extracellular matrix (ECM) in liver injury arises from increased synthesis by activated hepatic stellate cells and other hepatic fibrogenic cell types, as well as from bone marrow and circulating fibrocytes. Concurrently, degradation of ECM by matrix metalloproteinases (MMPs) fails to keep pace with increased synthesis, in part due to sustained expression of MMP inhibitors (e.g., tissue inhibitors of metalloproteinases). A growing list of circulating, paracrine, and autocrine mediators have been identified that amplify the fibrogenic response of liver. Combined with accelerating knowledge about signaling pathways and genetic determinants, major advances are anticipated in new diagnostics and therapies that will transform the care of patients with chronic liver diseases in the coming years.

KEYWORDS

Hepatic fibrogenesis - extracellular matrix - hepatic stellate cells - tissue inhibitors of metalloproteinases - signaling pathways

Volltext

Referenzen

REFERENCES

1 Schuppan D, Ruehl M, Somasundaram R, Hahn E G. Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis. 2001; 21 351-372
2 Rojkind M, Giambrone M A, Biempica L. Collagen types in normal and cirrhotic liver. Gastroenterology. 1979; 76 710-719
3 McGuire R F, Bissell D M, Boyles J, Roll F J. Role of extracellular matrix in regulating fenestrations of sinusoidal endothelial cells isolated from normal rat liver. Hepatology. 1992; 15 989-997
4 Corpechot C, Barbu V, Wendum D et al.. Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology. 2002; 35 1010-1021
5 Medina J, Arroyo A G, Sanchez-Madrid F, Moreno-Otero R. Angiogenesis in chronic inflammatory liver disease. Hepatology. 2004; 39 1185-1195
6 Arteel G E. Oxidants and antioxidants in alcohol-induced liver disease. Gastroenterology. 2003; 124 778-790
7 Parola M, Robino G. Oxidative stress-related molecules and liver fibrosis. J Hepatol. 2001; 35 297-306
8 Nieto N, Friedman S L, Cederbaum A I. Cytochrome P450 2E1-derived reactive oxygen species mediate paracrine stimulation of collagen I protein synthesis by hepatic stellate cells. J Biol Chem. 2002; 277 9853-9864
9 Galli A, Svegliati-Baroni G, Ceni E et al.. Oxidative stress stimulates proliferation and invasiveness of hepatic stellate cells via a MMP2-mediated mechanism. Hepatology. 2005; 41 1074-1084
10 Ankoma-Sey V, Wang Y, Dai Z. Hypoxic stimulation of vascular endothelial growth factor expression in activated rat hepatic stellate cells. Hepatology. 2000; 31 141-148
11 Wang Y Q, Luk J M, Ikeda K et al.. Regulatory role of vHL/HIF-1alpha in hypoxia-induced VEGF production in hepatic stellate cells. Biochem Biophys Res Commun. 2004; 317 358-362
12 Jeong W I, Do S H, Yun H S et al.. Hypoxia potentiates transforming growth factor-beta expression of hepatocyte during the cirrhotic condition in rat liver. Liver Int. 2004; 24 658-668
13 Henderson N C, Iredale J P. Liver fibrosis: cellular mechanisms of progression and resolution. Clin Sci (Lond). 2007; 112 265-280
14 Mehal W Z. Activation-induced cell death of hepatic stellate cells by the innate immune system. Gastroenterology. 2006; 130 600-603
15 Tsukamoto H. Redox regulation of cytokine expression in Kupffer cells. Antioxid Redox Signal. 2002; 4 741-748
16 Tomita K, Tamiya G, Ando S et al.. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut. 2006; 55 415-424
17 Sprenger H, Kaufmann A, Garn H, Lahme B, Gemsa D, Gressner A M. Induction of neutrophil-attracting chemokines in transforming rat hepatic stellate cells. Gastroenterology. 1997; 113 277-285
18 Marra F, Valente A J, Pinzani M, Abboud H E. Cultured human liver fat-storing cells produce monocyte chemotactic protein-1. Regulation by proinflammatory cytokines. J Clin Invest. 1993; 92 1674-1680
19 Guicciardi M E, Gores G J. Apoptosis: a mechanism of acute and chronic liver injury. Gut. 2005; 54 1024-1033
20 Canbay A, Feldstein A E, Higuchi H et al.. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology. 2003; 38 1188-1198
21 Zhan S S, Jiang J X, Wu J et al.. Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo. Hepatology. 2006; 43 435-443
22 Canbay A, Friedman S, Gores G J. Apoptosis: the nexus of liver injury and fibrosis. Hepatology. 2004; 39 273-278
23 Adams L A, Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med. 2005; 22 1129-1133
24 Caldwell S H, Chang C Y, Nakamoto R K, Krugner-Higby L. Mitochondria in nonalcoholic fatty liver disease. Clin Liver Dis. 2004; 8 595-617
25 Machado M, Cortez-Pinto H. Non-alcoholic steatohepatitis and metabolic syndrome. Curr Opin Clin Nutr Metab Care. 2006; 9 637-642
26 Fartoux L, Poujol-Robert A, Guéchot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut. 2005; 54 1003-1008
27 Walsh M J, Vanags D M, Clouston A D et al.. Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury. Hepatology. 2004; 39 1230-1238
28 Ekstedt M, Franzen L E, Mathiesen U L et al.. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006; 44 865-873
29 Walsh M J, Jonsson J R, Richardson M M et al.. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut. 2006; 55 529-535
30 Harrison S A, Brunt E M, Qazi R A et al.. Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2005; 3 604-609
31 Reeves H L, Burt A D, Wood S, Day C P. Hepatic stellate cell activation occurs in the absence of hepatitis in alcoholic liver disease and correlates with the severity of steatosis. J Hepatol. 1996; 25 677-683
32 McCullough A J. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol. 2006; 40(suppl 1) S17-S29
33 Farrell G C, Larter C Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006; 43(suppl 1) S99-S112
34 Issa R, Zhou X, Constandinou C M et al.. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology. 2004; 126 1795-1808
35 Benyon R C, Arthur M J. Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis. 2001; 21 373-384
36 Bigg H F, Rowan A D, Barker M D, Cawston T E. Activity of matrix metalloproteinase-9 against native collagen types I and III. FEBS J. 2007; 274 1246-1255
37 Iredale J P, Benyon R C, Arthur M J et al.. Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis. Hepatology. 1996; 24 176-184
38 Yoshiji H, Kuriyama S, Miyamoto Y et al.. Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology. 2000; 32 1248-1254
39 Murphy F R, Issa R, Zhou X et al.. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J Biol Chem. 2002; 277 11069-11076
40 Yoshiji H, Kuriyama S, Yoshii J et al.. Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse. Hepatology. 2002; 36 850-860
41 Parsons C J, Bradford B U, Pan C Q et al.. Antifibrotic effects of a tissue inhibitor of metalloproteinase-1 antibody on established liver fibrosis in rats. Hepatology. 2004; 40 1106-1115
42 Henderson N C, Mackinnon A C, Farnworth S L et al.. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA. 2006; 103 5060-5065
43 Maeda N, Kawada N, Seki S et al.. Stimulation of proliferation of rat hepatic stellate cells by galectin-1 and galectin-3 through different intracellular signaling pathways. J Biol Chem. 2003; 278 18938-18944
44 Ng V L, Sabla G E, Melin-Aldana H, Kelley-Loughnane N, Degen J L, Bezerra J A. Plasminogen deficiency results in poor clearance of non-fibrin matrix and persistent activation of hepatic stellate cells after an acute injury. J Hepatol. 2001; 35 781-789
45 Olaso E, Ikeda K, Eng F J et al.. DDR2 receptor promotes MMP-2-mediated proliferation and invasion by hepatic stellate cells. J Clin Invest. 2001; 108 1369-1378
46 Carloni V, Romanelli R G, Pinzani M, Laffi G, Gentilini P. Expression and function of integrin receptors for collagen and laminin in cultured human hepatic stellate cells. Gastroenterology. 1996; 110 1127-1136
47 Russo F P, Alison M R, Bigger B W et al.. The bone marrow functionally contributes to liver fibrosis. Gastroenterology. 2006; 130 1807-1821
48 Kisseleva T, Uchinami H, Feirt N et al.. Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J Hepatol. 2006; 45 429-438
49 Kalluri R, Neilson E G. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest. 2003; 112 1776-1784
50 Zeisberg M, Shah A A, Kalluri R. Bone morphogenic protein-7 induces mesenchymal to epithelial transition in adult renal fibroblasts and facilitates regeneration of injured kidney. J Biol Chem. 2005; 280 8094-8100
51 Xia J L, Dai C, Michalopoulos G K, Liu Y. Hepatocyte growth factor attenuates liver fibrosis induced by bile duct ligation. Am J Pathol. 2006; 168 1500-1512
52 Gawrieh S, Papouchado B G, Burgart L J, Kobayashi S, Charlton M R, Gores G J. Early hepatic stellate cell activation predicts severe hepatitis C recurrence after liver transplantation. Liver Transpl. 2005; 11 1207-1213
53 Friedman S L. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008; , In press
54 Schulze-Krebs A, Preimel D, Popov Y et al.. Hepatitis C virus-replicating hepatocytes induce fibrogenic activation of hepatic stellate cells. Gastroenterology. 2005; 129 246-258
55 Bataller R, Paik Y H, Lindquist J N, Lemasters J J, Brenner D A. Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology. 2004; 126 529-540
56 Schäffler A, Schölmerich J, Büchler C. Mechanisms of disease: adipocytokines and visceral adipose tissue-emerging role in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol. 2005; 2 273-280
57 Kaser S, Moschen A, Cayon A et al.. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut. 2005; 54 117-121
58 Friedman S L. Mechanisms of disease: mechanisms of hepatic fibrosis and therapeutic implications. Nat Clin Pract Gastroenterol Hepatol. 2004; 1 98-105
59 Iredale J P. Hepatic stellate cell behavior during resolution of liver injury. Semin Liver Dis. 2001; 21 427-436
60 Pinzani M. PDGF and signal transduction in hepatic stellate cells. Front Biosci. 2002; 7 d1720-d1726
61 Marra F, Grandaliano G, Valente A J, Abboud H E. Thrombin stimulates proliferation of liver fat-storing cells and expression of monocyte chemotactic protein-1: potential role in liver injury. Hepatology. 1995; 22 780-787
62 Yang C, Zeisberg M, Mosterman B et al.. Liver fibrosis: insights into migration of hepatic stellate cells in response to extracellular matrix and growth factors. Gastroenterology. 2003; 124 147-159
63 Patsenker E, Popov Y, Wiesner M, Goodman S L, Schuppan D. Pharmacological inhibition of the vitronectin receptor abrogates PDGF-BB-induced hepatic stellate cell migration and activation in vitro. J Hepatol. 2007; 46 878-887
64 Lee J S, Kang Decker N, Chatterjee S, Yao J, Friedman S, Shah V. Mechanisms of nitric oxide interplay with Rho GTPase family members in modulation of actin membrane dynamics in pericytes and fibroblasts. Am J Pathol. 2005; 166 1861-1870
65 Dooley S, Delvoux B, Lahme B, Mangasser-Stephan K, Gressner A M. Modulation of transforming growth factor beta response and signaling during transdifferentiation of rat hepatic stellate cells to myofibroblasts. Hepatology. 2000; 31 1094-1106
66 Pinzani M, Marra F. Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis. 2001; 21 397-416
67 Rockey D C. Vascular mediators in the injured liver. Hepatology. 2003; 37 4-12
68 Iredale J P. Cirrhosis: new research provides a basis for rational and targeted treatments. BMJ. 2003; 327 143-147
69 Okuno M, Kojima S, Akita K et al.. Retinoids in liver fibrosis and cancer. Front Biosci. 2002; 7 d204-d218
70 Li H, Zhang J, Huang G et al.. Effect of retinoid kappa receptor alpha (RXRalpha) transfection on the proliferation and phenotype of rat hepatic stellate cells in vitro. Chin Med J (Engl). 2002; 115 928-932
71 Hellemans K, Verbuyst P, Quartier E et al.. Differential modulation of rat hepatic stellate phenotype by natural and synthetic retinoids. Hepatology. 2004; 39 97-108
72 Paik Y H, Schwabe R F, Bataller R, Russo M P, Jobin C, Brenner D A. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology. 2003; 37 1043-1055
73 Paik Y H, Lee K S, Lee H J et al.. Hepatic stellate cells primed with cytokines upregulate inflammation in response to peptidoglycan or lipoteichoic acid. Lab Invest. 2006; 86 676-686
74 Brun P, Castagliuolo I, Pinzani M, Palu G, Martines D. Exposure to bacterial cell wall products triggers an inflammatory phenotype in hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol. 2005; 289 G571-G578
75 Viñas O, Bataller R, Sancho-Bru P et al.. Human hepatic stellate cells show features of antigen-presenting cells and stimulate lymphocyte proliferation. Hepatology. 2003; 38 919-929
76 Winau F, Hegasy G, Weiskirchen R et al.. Ito cells are liver-resident antigen-presenting cells for activating T cell responses. Immunity. 2007; 26 117-129
77 Safadi R, Ohta M, Alvarez C E et al.. Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology. 2004; 127 870-882
78 Radaeva S, Sun R, Jaruga B, Nguyen V T, Tian Z, Gao B. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology. 2006; 130 435-452
79 Jeong W I, Park O, Radaeva S, Gao B. STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity. Hepatology. 2006; 44 1441-1451
80 Ito T, Nemoto M. Uber die Kupfferschen Sternzellen und die ‘Fettspeicherungszellen’ (‘fat storing cells’) in der Blutkapillarenwand der menschlichen Leber. Okajimas Folia Anat Jpn. 1952; 24 243-258
81 Geerts A. On the origin of stellate cells: mesodermal, endodermal or neuro-ectodermal?. J Hepatol. 2004; 40 331-334
82 Cassiman D, Barlow A, Vander Borght S, Libbrecht L, Pachnis V. Hepatic stellate cells do not derive from the neural crest. J Hepatol. 2006; 44 1098-1104
83 Suskind D L, Muench M O. Searching for common stem cells of the hepatic and hematopoietic systems in the human fetal liver: CD34 + cytokeratin 7/8 + cells express markers for stellate cells. J Hepatol. 2004; 40 261-268
84 Kordes C, Sawitza I, Muller-Marbach A et al.. CD133⁺ hepatic stellate cells are progenitor cells. Biochem Biophys Res Commun. 2007; 352 410-417
85 Beaussier M, Wendum D, Schiffer E et al.. Prominent contribution of portal mesenchymal cells to liver fibrosis in ischemic and obstructive cholestatic injuries. Lab Invest. 2007; 87 292-303
86 Baba S, Fujii H, Hirose T et al.. Commitment of bone marrow cells to hepatic stellate cells in mouse. J Hepatol. 2004; 40 255-260
87 Forbes S J, Russo F P, Rey V et al.. A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology. 2004; 126 955-963
88 Bilzer M, Roggel F, Gerbes A L. Role of Kupffer cells in host defense and liver disease. Liver Int. 2006; 26 1175-1186
89 Duffield J S, Forbes S J, Constandinou C M et al.. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest. 2005; 115 56-65
90 Imamura M, Ogawa T, Sasaguri Y, Chayama K, Ueno H. Suppression of macrophage infiltration inhibits activation of hepatic stellate cells and liver fibrogenesis in rats. Gastroenterology. 2005; 128 138-146
91 Jarnagin W R, Rockey D C, Koteliansky V E, Wang S S, Bissell D M. Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis. J Cell Biol. 1994; 127 2037-2048
92 Sedlaczek N, Jia J D, Bauer M et al.. Proliferating bile duct epithelial cells are a major source of connective tissue growth factor in rat biliary fibrosis. Am J Pathol. 2001; 158 1239-1244
93 Kinnman N, Hultcrantz R, Barbu V et al.. PDGF-mediated chemoattraction of hepatic stellate cells by bile duct segments in cholestatic liver injury. Lab Invest. 2000; 80 697-707
94 Jhandier M N, Kruglov E A, Lavoie E G, Sévigny J, Dranoff J A. Portal fibroblasts regulate the proliferation of bile duct epithelia via expression of NTPDase2. J Biol Chem. 2005; 280 22986-22992
95 Kruglov E A, Nathanson R A, Nguyen T, Dranoff J A. Secretion of MCP-1/CCL2 by bile duct epithelia induces myofibroblastic transdifferentiation of portal fibroblasts. Am J Physiol Gastrointest Liver Physiol. 2006; 290 G765-G771
96 Novobrantseva T I, Majeau G R, Amatucci A et al.. Attenuated liver fibrosis in the absence of B cells. J Clin Invest. 2005; 115 3072-3082
97 Melhem A, Muhanna N, Bishara A et al.. Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. J Hepatol. 2006; 45 60-71
98 Crotta S, Stilla A, Wack A et al.. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med. 2002; 195 35-41
99 Tseng C T, Klimpel G R. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J Exp Med. 2002; 195 43-49
100 Mazzocca A, Sciammetta S C, Carloni V et al.. Binding of hepatitis C virus envelope protein E2 to CD81 up-regulates matrix metalloproteinase-2 in human hepatic stellate cells. J Biol Chem. 2005; 280 11329-11339
101 Kaisho T, Akira S. Toll-like receptor function and signaling. J Allergy Clin Immunol. 2006; 117 979-987
102 Schwabe R F, Seki E, Brenner D A. Toll-like receptor signaling in the liver. Gastroenterology. 2006; 130 1886-1900
103 Lee J Y, Ye J, Gao Z et al.. Reciprocal modulation of Toll-like receptor-4 signaling pathways involving MyD88 and phosphatidylinositol 3-kinase/AKT by saturated and polyunsaturated fatty acids. J Biol Chem. 2003; 278 37041-37051
104 Jiang D, Liang J, Fan J et al.. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med. 2005; 11 1173-1179
105 Lee J Y, Sohn K H, Rhee S H, Hwang D. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J Biol Chem. 2001; 276 16683-16689
106 Smiley S T, King J A, Hancock W W. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol. 2001; 167 2887-2894
107 Okamura Y, Watari M, Jerud E S et al.. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem. 2001; 276 10229-10233
108 Chen X, Sun Z, Du X, Liu C, Liu Y, Wu L. Study on the relationship between heat shock protein 70 and toll-like receptor-4 of monocytes. J Huazhong Univ Sci Technolog Med Sci. 2004; 24 560-562
109 Ohashi K, Burkart V, Flohe S, Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol. 2000; 164 558-561
110 Park J S, Svetkauskaite D, He Q et al.. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem. 2004; 279 7370-7377
111 Brunn G J, Bungum M K, Johnson G B, Platt J L. Conditional signaling by Toll-like receptor 4. FASEB J. 2005; 19 872-874
112 Yohe H C, O'Hara K A, Hunt J A et al.. Involvement of Toll-like receptor 4 in acetaminophen hepatotoxicity. Am J Physiol Gastrointest Liver Physiol. 2006; 290 G1269-G1279
113 Isogawa M, Robek M D, Furuichi Y, Chisari F V. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol. 2005; 79 7269-7272
114 Takayashiki T, Yoshidome H, Kimura F et al.. Increased expression of toll-like receptor 4 enhances endotoxin-induced hepatic failure in partially hepatectomized mice. J Hepatol. 2004; 41 621-628
115 Shi H, Kokoeva M V, Inouye K, Tzameli I, Yin H, Flier J S. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest. 2006; 116 3015-3025
116 Seki E, De Minicis S, Österreicher C H et al.. TLR4 mediates hepatic fibrosis by downregulating TGFβ pseudoreceptor BAMBI and enhancing TGFβ signaling. Nat Med. 2007; , In press
117 Breitkopf K, Godoy P, Ciuclan L, Singer M V, Dooley S. TGF-beta/Smad signaling in the injured liver. Z Gastroenterol. 2006; 44 57-66
118 Inagaki Y, Okazaki I. Emerging insights into transforming growth factor beta Smad signal in hepatic fibrogenesis. Gut. 2007; 56 284-292
119 Uemura M, Swenson E S, Gaça M D, Giordano F J, Reiss M, Wells R G. Smad2 and Smad3 play different roles in rat hepatic stellate cell function and alpha-smooth muscle actin organization. Mol Biol Cell. 2005; 16 4214-4224
120 Danen E H. Integrins: regulators of tissue function and cancer progression. Curr Pharm Des. 2005; 11 881-891
121 Xu Y, Gurusiddappa S, Rich R L et al.. Multiple binding sites in collagen type I for the integrins alpha1beta1 and alpha2beta1. J Biol Chem. 2000; 275 38981-38989
122 Zhou X, Murphy F R, Gehdu N, Zhang J, Iredale J P, Benyon R C. Engagement of alphavbeta3 (αvβ3) integrin regulates proliferation and apoptosis of hepatic stellate cells. J Biol Chem. 2004; 279 23996-24006
123 Sheppard D. Integrin-mediated activation of latent transforming growth factor beta. Cancer Metastasis Rev. 2005; 24 395-402
124 Wells R G. The role of matrix stiffness in hepatic stellate cell activation and liver fibrosis. J Clin Gastroenterol. 2005; 39 S158-S161
125 Jiang F, Parsons C J, Stefanovic B. Gene expression profile of quiescent and activated rat hepatic stellate cells implicates Wnt signaling pathway in activation. J Hepatol. 2006; 45 401-409
126 Brigstock D R. The CCN family: a new stimulus package. J Endocrinol. 2003; 178 169-175
127 Jiménez W. Endocannabinoids and liver disease. Hepatology. 2005; 41 983-985
128 Julien B, Grenard P, Teixeira-Clerc F et al.. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology. 2005; 128 742-755
129 Teixeira-Clerc F, Julien B, Grenard P et al.. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med. 2006; 12 671-676
130 Perwitz N, Fasshauer M, Klein J. Cannabinoid receptor signaling directly inhibits thermogenesis and alters expression of adiponectin and visfatin. Horm Metab Res. 2006; 38 356-358
131 Friedman S L. Reefer madness? Assessing the effects of cannabinoids with a less jaundiced eye. J Hepatol. 2007; 46 180-182
132 Gäbele E, Reif S, Tsukada S et al.. The role of p70S6K in hepatic stellate cell collagen gene expression and cell proliferation. J Biol Chem. 2005; 280 13374-13382
133 Sicklick J K, Li Y X, Choi S S et al.. Role for hedgehog signaling in hepatic stellate cell activation and viability. Lab Invest. 2005; 85 1368-1380
134 Neef M, Ledermann M, Saegesser H et al.. Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term. J Hepatol. 2006; 44 167-175
135 Hadziyannis S J, Tassopoulos N C, Heathcote E J et al.. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006; 131 1743-1751
136 Bonis P A, Friedman S L, Kaplan M M. Is liver fibrosis reversible?. N Engl J Med. 2001; 344 452-454
137 Herbst H, Wege T, Milani S et al.. Tissue inhibitor of metalloproteinase-1 and -2 RNA expression in rat and human liver fibrosis. Am J Pathol. 1997; 150 1647-1659
138 Desmet V J, Roskams T. Cirrhosis reversal: a duel between dogma and myth. J Hepatol. 2004; 40 860-867

Scott L FriedmanM.D.

Division of Liver Diseases, Mount Sinai School of Medicine

Box 1123, 1425 Madison Avenue, Room 1170C, New York, NY 10029

eMail: scott.friedman@mssm.edu